Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients
Journal of Clinical Immunology · 2023-11 · 43 (8) · 2091-2103
DOI: 10.1007/s10875-023-01587-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Immunology, online erschienen am 27.09.2023. Verfasst von Giulio Tessarin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, University of Brescia and ASST…. Hauptthemen laut MEDLINE: Common Variable Immunodeficiency, Lung Diseases, Interstitial. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Brescia.
Abstract (Originalsprache)
Granulomatous lymphocytic interstitial lung disease (GLILD) represents a fatal immune dysregulatory complication in common variable immunodeficiency (CVID). Evidence-based diagnostic guidelines are lacking, and GLILD treatment consists in immunosuppressive drugs; nonetheless, therapeutical strategies are heterogeneous and essentially based on experts’ opinions and data from small case series or case reports. We aimed to evaluate the efficacy and safety of first-line Rituximab monotherapy for CVID-related GLILD, by assessing symptoms and quality of life alterations, immunological parameters, pulmonary function tests, and lung computed tomography. All six GLILD patients received Rituximab infusions as a first-line treatment. Rituximab was administered at 375 mg/m 2 monthly for six infusions followed by maintenance every 3 months; none of the patients experienced severe adverse events. Symptom burden and quality of life significantly improved in treated patients compared to a control group of CVID patients without GLILD. Rituximab treatment indirectly caused a trend toward reduced T-cell activation and exhaustion markers sCD25 and sTIM-3. Lung function improved in treated patients, with statistically significant increases in TLC and DL CO . Lung CT scan findings expressed by means of Baumann scoring system displayed a reduction in the entire cohort. In conclusion, first-line monotherapy with Rituximab displayed high efficacy in disease remission in all treated patients, with improvement of symptoms and amelioration of quality of life, as well as restoration of PFTs and lung CT scan findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Sciences, Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, University of Brescia and ASST Spedali Civili of Brescia, Piazzale Spedali Civili 1, 25123, Brescia,…
- Department of Molecular and Translational Medicine, Institute for Molecular Medicine A. Nocivelli, University of Brescia, Brescia, Italy.
- Diagnostic Department, Flow Cytometry Laboratory, ASST Spedali Civili of Brescia, Brescia, Italy.
- Department of Medical and Surgical Specialties, Pediatric Radiology, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy.
ORCID-Profile: Vassilios Lougaris
Förderung
- Università degli Studi di Brescia
Zitieren
APA
Tessarin, G., Baronio, M., Gazzurelli, L., Rossi, S., Chiarini, M., Moratto, D., Giliani, S. C., Bondioni, M. P., Badolato, R., & Lougaris, V. (2023). Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients. Journal of Clinical Immunology, 43(8), 2091-2103. https://doi.org/10.1007/s10875-023-01587-4
Vancouver
Tessarin G, Baronio M, Gazzurelli L, Rossi S, Chiarini M, Moratto D, et al. Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients. Journal of Clinical Immunology. 2023;43(8):2091-2103. doi:10.1007/s10875-023-01587-4
BibTeX
@article{Tessarin2023,
author = {Tessarin, Giulio and Baronio, Manuela and Gazzurelli, Luisa and Rossi, Stefano and Chiarini, Marco and Moratto, Daniele and Giliani, Silvia Clara and Bondioni, Maria Pia and Badolato, Raffaele and Lougaris, Vassilios},
title = {Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients},
journal = {Journal of Clinical Immunology},
year = {2023},
volume = {43},
number = {8},
pages = {2091--2103},
doi = {10.1007/s10875-023-01587-4}
}
EUVIMED